Published in Proc Natl Acad Sci U S A on August 14, 2003
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci U S A (2005) 2.00
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J (2006) 1.92
The B7 family of immune-regulatory ligands. Genome Biol (2005) 1.74
Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev (2009) 1.72
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology (2008) 1.52
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A (2006) 1.46
BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol (2006) 1.45
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis. Clin Exp Immunol (2015) 1.40
Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev (2009) 1.39
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer (2013) 1.32
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res (2008) 1.21
The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival. Clin Dev Immunol (2011) 1.20
Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol Cell Biol (2006) 1.18
B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood (2008) 1.17
The contrasting role of B7-H3. Proc Natl Acad Sci U S A (2008) 1.15
Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med (2011) 1.14
No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol (2006) 1.13
Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol (2014) 1.13
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A (2013) 1.12
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res (2013) 1.11
The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene (2013) 1.06
Host b7x promotes pulmonary metastasis of breast cancer. J Immunol (2013) 1.05
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther (2011) 1.03
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clin Cancer Res (2014) 1.02
Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg (2011) 1.01
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med (2011) 1.01
B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation. PLoS One (2012) 1.00
Colonic epithelial cell mediated suppression of CD4 T cell activation. Gut (2004) 0.97
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw (2014) 0.96
Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes (2011) 0.96
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res (2009) 0.96
B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol (2012) 0.95
Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med (2009) 0.94
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res (2014) 0.94
Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World J Surg Oncol (2014) 0.93
Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep (2014) 0.93
Recent advances in dendritic cell biology. J Clin Immunol (2005) 0.92
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection. J Immunol (2012) 0.91
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol (2007) 0.90
The role of ICOS and other costimulatory molecules in allergy and asthma. Springer Semin Immunopathol (2004) 0.90
An odyssey of islet transplantation for therapy of type 1 diabetes. World J Surg (2007) 0.90
B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cells. Hepatology (2010) 0.89
Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. Onco Targets Ther (2013) 0.88
New battlefields for costimulation. J Exp Med (2006) 0.88
B7-H6 expression in non-small cell lung cancers. Int J Clin Exp Pathol (2014) 0.87
B7-H4 expression in various tumors determined using a novel developed monoclonal antibody. Clin Exp Med (2010) 0.87
Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol (2011) 0.86
The Relationship between B7-H4 Expression and Clinicopathological Characteristics in Clinical Stage T1 Conventional Renal Cell Carcinoma. Korean J Urol (2011) 0.86
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86
T cell costimulation and coinhibition: genetics and disease. Discov Med (2011) 0.85
T cell coinhibition and immunotherapy in human breast cancer. Discov Med (2012) 0.85
Murine isolated lymphoid follicles contain follicular B lymphocytes with a mucosal phenotype. Am J Physiol Gastrointest Liver Physiol (2006) 0.85
B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. J Autoimmun (2013) 0.85
Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med (2012) 0.84
B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation. Cancer Sci (2016) 0.84
Intracellular B7-H4 suppresses bile duct epithelial cell apoptosis in human primary biliary cirrhosis. Inflammation (2011) 0.83
B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol (2014) 0.83
Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol Lett (2011) 0.83
Development of a novel monoclonal antibody to B7-H4: characterization and biological activity. Eur J Med Res (2011) 0.83
B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. Clin Cancer Res (2016) 0.82
B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities. Oncoimmunology (2013) 0.82
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Urology (2009) 0.81
Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res Ther (2004) 0.81
Novel Immune Check-Point Regulators in Tolerance Maintenance. Front Immunol (2015) 0.81
B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients. Mol Clin Oncol (2013) 0.80
Nardilysin-dependent proteolysis of cell-associated VTCN1 (B7-H4) marks type 1 diabetes development. Diabetes (2014) 0.80
T-cell tolerance in cancer. Immunotherapy (2013) 0.79
Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis. Oncotarget (2016) 0.79
Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2016) 0.79
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy. Mol Ther (2016) 0.78
Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol (2016) 0.78
B7-H4 gene polymorphisms are associated with sporadic breast cancer in a Chinese Han population. BMC Cancer (2009) 0.78
B7-H4 Pathway in Islet Transplantation and β-Cell Replacement Therapies. J Transplant (2011) 0.78
B7-H4's role "beyond the tumor". Inflammation (2013) 0.78
B7-H4 expression is elevated in human U251 glioma stem-like cells and is inducible in monocytes cultured with U251 stem-like cell conditioned medium. Chin J Cancer (2013) 0.77
Blockade of both B7-H4 and CTLA-4 co-signaling pathways enhances mouse islet allograft survival. Islets (2012) 0.77
Upregulation of the B7/CD28 family member B7-H3 in bladder cancer. Oncol Lett (2014) 0.77
Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes. J Immunol (2016) 0.77
Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases. Oncotarget (2016) 0.77
Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy (2009) 0.77
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev (2017) 0.77
B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma. Oncol Lett (2014) 0.77
Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev (2017) 0.77
Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma. J Cancer (2015) 0.76
Increased B7-H4 expression during esophageal squamous cell carcinogenesis is associated with IL-6/STAT3 signaling pathway activation in mice. Oncol Lett (2017) 0.75
Aberrant expression of B7‑H4 may contribute to the development of hepatocellular carcinoma. Mol Med Rep (2016) 0.75
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
The B7-CD28 superfamily. Nat Rev Immunol (2002) 7.24
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol (2001) 3.41
B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity (2003) 3.18
B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity (1999) 2.94
Characterization of mouse and human B7-H3 genes. J Immunol (2002) 2.86
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol (2000) 2.13
Structure and evolution of the extended B7 family. Immunol Today (1999) 1.90
The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol (2001) 1.90
Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood (2000) 1.76
The cluster of BTN genes in the extended major histocompatibility complex. Genomics (2001) 1.48
The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol (2002) 1.44
T-cell stimulation: an abundance of B7s. Nat Med (1999) 1.32
Extending the B7 (CD80) gene family. Protein Sci (1994) 1.22
LICOS, a primordial costimulatory ligand? Curr Biol (2000) 1.19
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol (2007) 3.25
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol (2011) 2.80
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Chitinase and Fizz family members are a generalized feature of nematode infection with selective upregulation of Ym1 and Fizz1 by antigen-presenting cells. Infect Immun (2005) 2.51
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Proteases in parasitic diseases. Annu Rev Pathol (2006) 2.26
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity (2004) 2.21
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med (2010) 2.20
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev (2008) 2.08
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008) 1.99
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med (2011) 1.95
T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity (2007) 1.92
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity (2011) 1.85
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res (2009) 1.77
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One (2011) 1.73
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol (2010) 1.68
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A (2012) 1.64
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol (2004) 1.60
Therapeutic helminth infection of macaques with idiopathic chronic diarrhea alters the inflammatory signature and mucosal microbiota of the colon. PLoS Pathog (2012) 1.52
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res (2011) 1.47
Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol (2011) 1.47
Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev (2009) 1.47
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med (2010) 1.42
Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol (2005) 1.34
Monoclonal antibodies in cancer therapy. Cancer Immun (2012) 1.31
Identification of cooperative monomeric Brachyury sites conferring T-bet responsiveness to the proximal IFN-gamma promoter. Int Immunol (2003) 1.29
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med (2013) 1.29
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood (2004) 1.28
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A (2007) 1.28
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A (2010) 1.27
Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol (2012) 1.26
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 1.25
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22
Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res (2010) 1.22
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy (2009) 1.21
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res (2008) 1.21
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med (2014) 1.18
Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A (2012) 1.16
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol (2006) 1.15
Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol (2010) 1.15
Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med (2011) 1.14
Delineation of diverse macrophage activation programs in response to intracellular parasites and cytokines. PLoS Negl Trop Dis (2010) 1.14
Upregulation of retinal dehydrogenase 2 in alternatively activated macrophages during retinoid-dependent type-2 immunity to helminth infection in mice. PLoS Pathog (2012) 1.13
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother (2011) 1.10
Full-length-enriched cDNA libraries from Echinococcus granulosus contain separate populations of oligo-capped and trans-spliced transcripts and a high level of predicted signal peptide sequences. Mol Biochem Parasitol (2002) 1.09
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother (2008) 1.09
Cytokine-dependent inflammatory cell recruitment patterns in the peritoneal cavity of mice exposed to the parasitic nematode Brugia malayi. Med Microbiol Immunol (2002) 1.09
Helminthic therapy: improving mucosal barrier function. Trends Parasitol (2012) 1.06
Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell (2007) 1.05
Breaking down the barriers to cancer immunotherapy. Nat Immunol (2005) 1.04
MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest (2015) 1.03
Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proc Natl Acad Sci U S A (2005) 1.00
ETS transcription factor Erm controls subsynaptic gene expression in skeletal muscles. Neuron (2007) 1.00